ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Paul Tudor Jones / Tudor | 61 | New buy | 73,502 | $4,027,910 | 0.0% |
| Steve Cohen / Point72 | 75 | Trimmed -14% | 380,000 | $20,824,000 | 0.0% |
| Filed | Form | Activist | % of class | Conviction | |
|---|---|---|---|---|---|
| 2026-04-29 | SCHEDULE 13D/A | ORBIMED ADVISORS LLC | 13.1% | High | filing |
| 2026-04-21 | SCHEDULE 13D | Omega Fund VI, L.P. | 8.4% | Med | filing |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.